Lonza partners with immunotherapy centres on automated platform-based cell therapy manufacturing

9 Mar 2020

Lonza is partnering with three major immunotherapy academic and research centres to tech transfer their cell therapy manufacturing processes into an automated platform, the Switzerland-based CDMO said Monday.

The manufacturing processes were developed at the Stanford University School of Medicine, Fred Hutchinson Cancer Research Center and Parker Institute for Cancer Immunotherapy and will be transferred to Lonza’s Cocoon, an automated patient-scale cell therapy manufacturing platform.

Lonza partners with immunotherapy centres on automated platform-based cell therapy manufacturing

Lonza said process development will be shared between each partner and its R&D site in Shady Grove, US, allowing assessment of Cocoon’s automation, flexibility and scalability.

“The use of automated manufacturing systems will be a crucial element for academic-clinical centers seeking to succeed as a point-of-care manufacturing for patient-scale cell therapies,” Lonza said in a statement.

“We believe that using the Cocoon platform for decentralized cell therapy manufacturing at clinical centers, in addition to centralized locations, will convey significant benefits in costs, scalability, and lead time to deliver novel cell therapies to those patients most in need,” said Eytan Abraham, Head of Personalized Medicine, Lonza Pharma & Biotech.

In 2018 Lonza bought Octane Biotech, the company that had been developing Cocoon, and then last year announced a collaboration with Sheba Medical Center in Israel to develop point-of-care cell therapy manufacturing using Cocoon.